NovaTechs BV was founded in 2020 in the Netherlands, driven by a passion for innovation and a commitment to improving drug delivery in oncology. Our research on hydrogels began in 2008, focusing on nano-pharmaceuticals and targeted therapeutics. This work led us to develop advanced delivery platforms like nanogels and in-situ gel systems. As we recognized a significant gap in interventional oncology, we shifted our focus to creating more effective and safer cancer treatments.
